Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. - Wikidata - awgldk - TriplyDB

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

http://www.wikidata.org/entity/Q36157197

about

Novel therapeutic targets for pancreatic cancer Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Regulation and Role of EZH2 in Cancer Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma Small-molecular modulators of cancer-associated epigenetic mechanisms.The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.Update of research on the role of EZH2 in cancer progression.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Targeting of cancer stem cells by inhibitors of DNA and histone methylation.Pathobiology of pancreatic cancer: implications on therapy.The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery.miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.The promise of epigenomic therapeutics in pancreatic cancer Polycomb Repressor Complex 2 in Genomic Instability and Cancer Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma.Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.

P2860

Q24564267-AFCC43DD-CDBB-40FB-8791-2F86720131C1 Q26781923-A363ADF7-4733-446F-B08C-F0F8F08F0CA4 Q28074465-24FA1375-8B21-4311-98AF-725A301CD01A Q28076548-02CC7D1F-40B4-42B7-8708-C7C44C19F278 Q28535154-8885C967-DB6F-45E1-B39F-D47C35E64759 Q33741828-5C9DBCAB-3E11-4E7B-AA8A-51B541DCEF57 Q33801377-5646A50B-B3C2-4B81-AFCE-F74F406B1868 Q33914216-58080925-B61A-441D-8AD2-E7242D298770 Q34043370-9F94D23E-29CF-48AC-86EF-32647E094849 Q34221829-043AE11D-D0FD-4456-BB2C-AD816F7C271F Q34628002-162E5A3F-07AB-4F47-9BE6-372DC3F96895 Q35014682-81F06EB7-6AC0-4D06-822E-6B0F4723230F Q35163440-A3A3BD8A-EC5B-4318-B6CF-F8777FE12F1F Q36567573-26CD72CF-D2B3-4375-BE0F-1BCF3833D167 Q36791100-DA9FF206-51C8-4EA3-BDC6-23C156BB1A5B Q37491122-A06AD6A3-D7C1-46BC-BE15-E736A7EAF32E Q37569554-6A921D64-AB6F-4426-B23E-AFBDC7E3718E Q38099319-EE565765-015D-4B7A-95AF-B341B59B19F6 Q38125770-F3FA7C54-A24E-496F-AB17-8BC20AE73971 Q38500320-A691A494-2DD0-46B5-88A1-F9933D5F7389 Q38664687-1C4BA0AE-739A-475E-98F6-6B5D74101D0D Q38704582-D8CE185A-10EC-4D61-A1F1-F0B1951A4BE0 Q38812898-74348487-AD15-404F-AD59-0DAF53980F57 Q38983476-D7C381B0-4776-4EB9-866B-CAD4567151A9 Q39068039-34D258A7-6D82-4062-A008-4E0AABFB088B Q39204274-2B2A5968-2C2F-42E6-B193-5A6185DC9E11 Q39985681-2EFF3EBB-9838-4207-9A11-83714ED131C3 Q41473804-4C0A9DEB-7EA8-4A78-9976-887FE38931D9 Q41573279-0477C47A-D27E-4527-97F7-6F4543E5E407 Q42688119-39F5E0D7-0DED-432C-9DD5-9522E3DAA084 Q45205085-E8156BA7-9130-4B68-B1B8-1BD661F5DB0D Q47630151-D4379F93-E315-4CC4-BBAA-6EF36463FE6C Q47931449-4A02F5FD-0F94-4AE3-B8FC-56512F840187 Q50545391-4869551C-8DF4-4674-B732-F465FF41437E

P2860

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

http://www.wikidata.org/entity/Q36157197

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@ast

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@en

type

label

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@ast

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@en

prefLabel

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@ast

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@en

P1433

Q36157197-71694D2F-B1E8-499E-A6F4-6D2B195BD539

P1476

Q36157197-3207BF72-7B4A-456A-AD8C-026C3A0D3BDC

P2093

Q36157197-0190961D-2F2B-4BFB-8117-649FAA961BA1

Q36157197-0199827B-2435-4E17-AF81-631384FB133C

Q36157197-0D7C6A04-A9A7-44EC-97D8-73CCC830A31F

Q36157197-1971EEFD-F673-4A86-ABEC-6AF742D75E01

Q36157197-278F8271-8C71-4501-B732-250C66F78A3B

Q36157197-37166CCA-56CA-45ED-A429-08893F7B310D

Q36157197-4BA50439-B611-4EC0-B91F-C4C518B5B701

Q36157197-704E5A4F-ED1A-4E23-AC5B-3F2B419ECB3A

Q36157197-9D4CC054-6339-439E-A7EA-9D9508A3688E

Q36157197-F904276A-7473-495D-8DB2-61F9CB760177

P2860

Q36157197-00C5B479-4C17-40BE-B0A4-2922F490FA85

Q36157197-02F08C79-E277-4B7B-8B0C-DDED5571FCDD

Q36157197-046A0E7B-81CF-4D4B-BA0F-453866502878

Q36157197-09430ADB-3CC5-4952-A095-E5E893D57CE1

Q36157197-11345A17-0F2A-4C13-A72A-128C2AE476BB

Q36157197-29A5204F-7D47-49EB-A674-7894AE58636F

Q36157197-2F1FA0F1-6AA6-47DB-9A2E-2F2D9F8BF448

Q36157197-457A3FF9-AD4E-4ED6-B550-B55FB10E91BE

Q36157197-4832DD96-A95B-400F-A653-DA513EEBE359

Q36157197-48953437-C94B-4B37-AB66-6A54C5EBB82F

P304

Q36157197-E3B7F898-18D4-476A-98F7-30220E863252

P31

Q36157197-7910E2F4-AE33-471D-8D95-493165753050

P356

Q36157197-D1E1958D-978E-42EA-AC24-EF01D17DF2F1

P433

Q36157197-34084034-9202-4AD3-B4CF-410DE6C7784A

P478

Q36157197-79ECE75E-29C4-489A-862B-EB3B56E30F29

P577

Q36157197-382073CB-F157-495F-91A6-AF0BE78DACC0

P5875

Q36157197-0B394970-DE9F-42F6-A9C7-ACBD0E81ACD6

P698

Q36157197-BC93AB93-E600-43E0-AA90-0D076F4677F4

P932

Q36157197-24CFDBD0-D2DB-4AE0-A193-EE0F352882A4

P356

1535-7163.MCT-12-0037

P1433

Molecular Cancer Therapeutics

P1476

Molecular mechanisms involved ...... ne in pancreatic cancer cells.

@en

P2093

Amir Avan

http://www.w3.org/2001/XMLSchema#string

Elena Galvani

http://www.w3.org/2001/XMLSchema#string

Elisa Giovannetti

http://www.w3.org/2001/XMLSchema#string

Elisa Paolicchi

http://www.w3.org/2001/XMLSchema#string

Francesco Crea

http://www.w3.org/2001/XMLSchema#string

Godefridus J Peters

http://www.w3.org/2001/XMLSchema#string

Niccola Funel

http://www.w3.org/2001/XMLSchema#string

Richard J Honeywell

http://www.w3.org/2001/XMLSchema#string

Romano Danesi

http://www.w3.org/2001/XMLSchema#string

Victor E Marquez

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

The Polycomb group protein EZH2 directly controls DNA methylation

Chromatin "prepattern" and histone modifiers in a fate choice for liver and pancreas

miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

P304

1735-1746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-12-0037

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225058331

http://www.w3.org/2001/XMLSchema#string

P698

22622284

http://www.w3.org/2001/XMLSchema#string

P932

3416916

http://www.w3.org/2001/XMLSchema#string